HIK.L Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 12:24):

Stats
Today's Volume	636 609
Average Volume	624 694
Market Cap	4.11B
EPS	£0 ( 2024-02-22 )
Last Dividend	£25.00 ( 2023-08-10 )
Next Dividend	£0 ( N/A )
P/E	27.26
ATR14	£1.029 (0.06%)

Volume Correlation

Long: -0.03 (neutral)

Short: 0.70 (moderate)

Signal:(60.503) Neutral

Hikma Pharmaceuticals PLC Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Hikma Pharmaceuticals PLC Correlation - Currency/Commodity

-0.07
( neutral )

0.01
( neutral )

0.72
( moderate )

-0.50
( neutral )

0.08
( neutral )

-0.35
( neutral )

Hikma Pharmaceuticals PLC Financials

Annual	2023
Revenue:	£2.88B
Gross Profit:	£1.39B (48.35 %)
EPS:	£0.860

Q4	2023
Revenue:	£1.45B
Gross Profit:	£692.00M (47.79 %)
EPS:	£0.260

Q2	2023
Revenue:	£1.43B
Gross Profit:	£715.00M (50.11 %)
EPS:	£0.590

Q4	2022
Revenue:	£1.30B
Gross Profit:	£642.00M (49.23 %)
EPS:	£0.0678

Financial Reports:

No articles found.

Hikma Pharmaceuticals PLC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
£16.00 (N/A)	£0 (N/A)	£29.52 (N/A)	£0 (N/A)	£25.00 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)

Hikma Pharmaceuticals PLC Dividend Information - Dividend Knight

Dividend Sustainability Score: 9.93 - good (99.32%) | Divividend Growth Potential Score: 3.85 - Decrease likely (22.92%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	£0.500	2006-04-26
Last Dividend	£25.00	2023-08-10
Next Dividend	£0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	36	--
Total Paid Out	£347.38	--
Avg. Dividend % Per Year	1.60%	--
Score	4.07	--
Div. Sustainability Score	9.93
Div.Growth Potential Score	3.85
Div. Directional Score	6.89	--

Next Divdend (Est)
(2024-06-25)

£25.96 Estimate 7.54 %

Dividend Stability

0.30 Poor

Dividend Score

4.07

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
2006	£0	0.00%
2007	£0	0.00%
2008	£0	0.00%
2009	£0	0.00%
2010	£0	0.00%
2011	£0	0.00%
2012	£0	0.00%
2013	£0	0.00%
2014	£0	0.00%
2015	£0	0.00%
2016	£0	0.00%
2017	£0	0.00%
2018	£25.40	1.92%
2019	£34.00	1.99%
2020	£36.22	1.82%
2021	£37.70	1.47%
2022	£42.00	1.92%
2023	£54.52	3.36%
2024	£0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for LSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SNWS.L	Dividend Knight	2023-06-08	Annually	32	4.00%
JCH.L	Dividend King	2023-07-27	Quarterly	52	2.72%
BVIC.L	Dividend Knight	2023-05-25	Annually	19	1.45%
PGOO.L	Dividend Knight	2023-07-06	Semi-Annually	23	3.14%
FSG.L	Dividend Knight	2023-09-28	Semi-Annually	4	0.98%
AFM.L	Dividend Knight	2023-09-07	Annually	8	1.57%
TEG.L	Dividend Knight	2023-10-05	Annually	8	1.00%
LLOY.L	Dividend Knight	2023-08-03	Annually	29	2.99%
CMCX.L	Dividend Knight	2023-07-13	Semi-Annually	9	0.03%
RECI.L	Dividend King	2023-09-21	Quarterly	19	5.01%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0661	1.500	8.68	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0406	1.200	8.65	10.00	[0 - 0.3]
returnOnEquityTTM	0.0866	1.500	-0.149	-0.223	[0.1 - 1]
payoutRatioTTM	0.721	-1.000	2.79	-2.79	[0 - 1]
currentRatioTTM	1.568	0.800	7.16	5.73	[1 - 3]
quickRatioTTM	0.831	0.800	9.82	7.85	[0.8 - 2.5]
cashRatioTTM	0.153	1.500	-0.261	-0.391	[0.2 - 2]
debtRatioTTM	0.254	-1.500	5.76	-8.64	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	2.68	2.00	9.11	10.00	[0 - 30]
freeCashFlowPerShareTTM	1.939	2.00	9.03	10.00	[0 - 20]
debtEquityRatioTTM	0.542	-1.500	7.83	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.489	1.000	5.18	5.18	[0.2 - 0.8]
operatingProfitMarginTTM	0.215	1.000	7.69	7.69	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.510	1.000	8.28	8.28	[0.2 - 2]
assetTurnoverTTM	0.614	0.800	9.24	7.39	[0.5 - 2]
Total Score				9.93

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	26.93	1.000	7.38	0	[1 - 100]
returnOnEquityTTM	0.0866	2.50	-0.0956	-0.223	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.939	2.00	9.35	10.00	[0 - 30]
dividendYielPercentageTTM	2.96	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	2.68	2.00	9.11	10.00	[0 - 30]
payoutRatioTTM	0.721	1.500	2.79	-2.79	[0 - 1]
pegRatioTTM	-110.20	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.211	1.000	7.21	0	[0.1 - 0.5]
Total Score				3.85

Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.